Table 3.
Risk factors | Definition |
Higher dose of dabigatran and edoxaban | Dabigatran: a dose of 150 mg b.i.d |
Edoxaban: a dose of 60 mg daily | |
Concomitant use of ulcerogenic agents | Antiplatelet agents, NSAIDs or steroid |
Older age | Age ≥ 75 years |
Renal impairment | Creatinine clearance < 50 mL/min |
Prior history of peptic ulcers or GIB | |
Helicobacter pylori infection | |
Pre-existing GI tract lesions | Examples like diverticulosis, angiodysplasias |
Ethnicity | Western population |
HAS-BLED score | Score of ≥ 3 |
Protective factors | Definition |
Gastroprotective agents | Proton pump inhibitors or histamine H2-receptor antagonists |
NOAC: Novel oral anticoagulant; GIB: Gastrointestinal bleeding; NSAIDs: Non-steroidal anti-inflammatory drugs.